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INTRODUCTION
On 7 December 2015, the British Society
of Gastroenterology and the Royal College
of Physicians held a joint conference: GI
cancer in the UK: can we do better? The
meeting was timely as, although outcomes
for patients with most gastrointestinal
cancers in the UK have steadily improved
in the past 10 years, survival figures remain
substantially worse than in many other
comparable nations.
After defining the scale of the problem,
the issues around early diagnosis were
discussed. Screening as prevention has
huge potential where there are defined
premalignant conditions. Uptake into the
Bowel Cancer Screening Programme
(BCSP) is variable but in some areas
remains low. It is hoped that with the
National Screening Committee recom-
mendation to replace the guaiac faecal
occult blood test (gFOBT) with the faecal
immunochemical test (FIT), the planned
age extension and the continued roll-out
of bowel scope screening by the National
Health Service (NHS) will extend the
value of the programme further.
The view from primary care suggested
that many factors affect the decision to
make a referral for suspected cancer.
Lack of direct access to testing was high-
lighted as a concern, as was the com-
pounding issue of the many patients who
delay seeking care. The Independent
Cancer Force is the latest of several
bodies calling for general practitioners
(GPs) to be able to refer ‘direct to test’.
However, a particular concern from sec-
ondary care relates to further stretching
of diagnostic resources already under
pressure—and how that can be addressed
in times of austerity. Waiting times for
endoscopy have begun to rise, yet capacity
to expand is limited. Training, recruitment
and retention of clinical staff were all
highlighted as key issues limiting the avail-
ability of these procedures. Various prac-
tical ways to improve detection with
endoscopy were proposed, as were pos-
sible ways to support and retain staff.
While much discussion related to colo-
rectal cancer (CRC), the conference also
heard about innovative methods of
addressing the substantial problem of
preventing oesophageal and pancreatic
cancer, or at least making the diagnosis
early enough to influence survival. As well
as describing the presentations, this report
attempts to capture the key points that
emerged from the audience discussions.
CANCER SURVIVAL
Professor Michel Coleman of the London
School of Hygiene and Tropical Medicine
discussed learning from the vast amount
of data on cancer survival. Epidemiological
studies and cancer registries provide a
wide range of information on incidence,
survival, prevalence, quality of life and
mortality at the population level. Such
data can help inform national cancer strat-
egy and health service planning, but they
provide few answers to doctors assessing
individual patients. Clinical trials obtain
evidence from highly selected patient
groups who do not reflect the broader
population and frequently present only
the highest achievable survival. In the real
world, cancer survival is unequal across
populations.
A clear downward gradient is seen in
cancer survival from the most to the least
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affluent socio-economic groups. Overall survival has
improved in the past 20–30 years, but that has mainly
been driven by improvements in the more affluent
groups, meaning the gradient has grown steeper.1
Additionally, in the 1990s, 5-year relative survival in
England, Scotland and Wales for colon cancer was
well below the average for Europe.2 This situation led
to the launch of the NHS Cancer Plan in England in
2000, which seemed to improve 1-year survival from
2003 onwards for various cancers.3
For CRC, postoperative outcomes in England vary
substantially between hospitals and NHS trusts.4 In
1998–2006, across 150 NHS trusts, 30-day post-
operative mortality was 6.7% overall. Leading prog-
nostic factors were age, comorbidity, Dukes stage at
diagnosis, deprived socio-economic status and opera-
tive urgency. Five-year survival is positively affected
by survival in the first year.5 Avoidable premature
deaths have declined to some degree, but if survival
for CRC in Britain had been as high as the highest in
Europe from 1995 to 1999, 8429 fewer premature
deaths would have occurred.6 For rectal cancer, if the
3-year survival in the least affluent group had been as
high as that in the most affluent group, around 600
premature deaths per year would have been avoided
during 1996–2000.7
In countries where patients have universal access to
healthcare, trends for 1-year and 5-year survival are
roughly parallel and have changed little over time
(figure 1).8 Some differences are seen for stage at
diagnosis and excess deaths.9 These values, however,
are difficult to compare against countries with other
types of healthcare systems because of incomplete
data. Staging is also classified with multiple different
systems, none of which allows complete mapping
from the others. Routine recording of disease stage at
diagnosis (eg, in registries) and standardisation of the
methods or data, which might allow mapping by algo-
rithms, would be extremely useful.10
The CONCORD-2 study11 has initiated global sur-
veillance of cancer survival based on individual data
for 25.7 million patients with cancer diagnosed as
having one of 10 common cancers between 1995 and
2009, provided by 279 cancer registries in 67 coun-
tries. For CRC, age-standardised net survival was
lower in the UK than in many other countries in
Europe, although the overall differences between
countries were small. Rankings in Asia improved
vastly, mainly due to aggressive strategies for early-
stage identification and treatment. Compared with
other cancers such as breast cancer in countries with
universal access to healthcare, survival trends for CRC
were much worse.
Irrespective of how large or small the numbers of
potentially avoidable deaths, what remains important
is that they are not being avoided. Stage at diagnosis is
recognised as a crucial factor for survival, but full
understanding of its contribution is hindered by dif-
ferences in coding between registries and incomplete
data. Wider consensus is needed on recording of data
on stage at diagnosis and on the methods by which
cancer stage is determined.10
SCREENING FOR GASTROINTESTINAL CANCERS
Screening for gastrointestinal cancer was addressed by
Professor Robert Steele, University of Dundee. Bowel,
stomach, liver and oesophageal cancers are among the
10 most commonly diagnosed cancers worldwide.
Early detection of these malignancies or precursor
conditions could improve outcomes. Screening is an
option, although its benefits are debated.
Programmatic screening aims to detect disease or
disease precursors in asymptomatic individuals and,
therefore, is only suitable if the disease is common
and treatable and early diagnosis will improve the
effectiveness of treatment.12 Without improved sur-
vival, screening merely leads to patients knowing
about their disease for longer. The method of screen-
ing must be acceptable to society. A drawback of pro-
grammatic screening is that it is subject to various
biases, such as self-selection (volunteers being dis-
posed to seek healthcare or being health conscious),
lead-time (erroneous extension of survival due to
early detection) and length bias (increased survival
within a given time frame because of a long latency or
preclinical period).13 To prove whether screening
works, individuals who do and do not participate
must be followed up.
Programme validity is determined by outcomes and
costs, including whether screening does any harm (eg,
overdiagnosis leading to unnecessary tests or treat-
ments in people with low-risk cancers), which should
be established with randomised controlled trials.14
The diagnostic tests for most gastrointestinal cancers
are not supported by extensive data from randomised
controlled trials and, therefore, do not meet all the
criteria for screening. Some approaches do show
Figure 1 Age-standardised 1-year and 5-year relative survival
trends 1995–2007 in countries with universal healthcare
systems.8
Forgacs I, et al. Frontline Gastroenterology 2018;9:49–61. doi:10.1136/flgastro-2016-10071350
Education
group.bmj.com on February 28, 2018 - Published by http://fg.bmj.com/Downloaded from 
promise: direct endoscopy, Helicobacter pylori status
and measurement of pepsinogen and gastrin 17 for
stomach cancer; direct endoscopy and cytology for
oesophageal cancer; and radiological imaging of
patients with cirrhosis, hepatitis B virus infection or
primary biliary cirrhosis for liver cancer. By contrast,
the α-fetoprotein blood test shows poor sensitivity for
liver cancer and no tests are yet suggested for pancre-
atic cancer.
Screening for large bowel cancer with the gFOBT
meets all the criteria,15–18 which has led to the BCSP
being introduced across the UK. In a pilot study from
2000 to 2006 in Scotland, CRC mortality was com-
pared in people aged 50–69 years offered screening
and those not offered screening. The groups were
matched for sex and socio-economic status. A 10%
relative reduction in CRC mortality was seen (0.90,
95% CI 0.83 to 0.99) in the population as a whole,
and among study participants alone the relative reduc-
tion was 27% (0.73, 95% CI 0.65 to 0.82).19
Screening by colonoscopy has a positive predictive
value of 15% for carcinoma, 36% for adenoma and
49% for no neoplasia. With this method, though,
interval cancers are a problem, especially in women in
whom fewer cancers but more interval cancers are
detected than in men.20
The FIT is proposed to replace gFOBT to improve
specificity for human haemoglobin and because it is
easier to perform and yields quantitative results. In
40 125 participants, FIT screening led to 909 (2.26%)
referrals for colonoscopy and detection of 30 cancers
and 31 interval cancers. Uptake of FIT is higher than
that of gFOBT in men and by people in lower socio-
economic groups.21 The cut-off for positivity is cur-
rently 2.0%, but reducing this threshold would
improve detection of interval cancers. The number of
colonoscopy referrals would increase, but would
remain lower than with no screening.
Sigmoidoscopy improves detection of high-risk
adenomas in people aged 55–64 years, has reduced
CRC mortality and incidence by 23% (HR 0.77, 95%
CI 0.70 to 0.84) and 31% (0.69, 95% CI 0.59 to
0.82), respectively, and has good uptake.22 Of note,
though, when assessed by cancer site, incidence was
reduced by 50% for distal cancers, but by only 3%
for proximal cancers. In England, one-off flexible sig-
moidoscopy is available to the public at age 55 years,
but only by request or offer. In Scotland, a rando-
mised controlled trial of flexible sigmoidoscopy is
underway in people aged around 60 years. Flexible
sigmoidoscopy should be rolled out across the UK
soon to increase screening options, although it is
unlikely to alter the socio-economic uptake gradi-
ent.23 Colonoscopy has excellent sensitivity and speci-
ficity for cancer and adenoma,24 but also has little
effect on proximal cancers.25
Several new screening approaches are on the
horizon but require much more assessment:
multitarget faecal DNA testing, which is more sensi-
tive but less specific than FIT (although that might
improve if the cut-off were altered); peripheral blood
tests for methylated DNA, tumour-associated proteins,
miRNA and autoantibodies; detection of volatile
organic compounds (dogs can detect these with 91%
sensitivity and 99% specificity in breath and with
97% and 99% in stools); CT/MRI; and capsule
endoscopy. Whether these will lessen the effects of
socio-economic status remains to be seen.
EARLY DIAGNOSIS OF GASTROINTESTINAL
CANCERS
Early diagnosis is important for all gastrointestinal
cancers, although the best data are currently available
for CRC. The 10-year survival has improved signifi-
cantly since the 1970s, being 90% in people with stage
I bowel cancer at diagnosis, compared with <10% in
people who present with stage IV disease.26 Yet only
45% of bowel cancer is diagnosed at an early stage.
Emergency presentation of many types of gastrointes-
tinal cancer remains all too common, leading to nega-
tive patient experience and poor outcomes.26
Dr Sara Hiom of Cancer Research UK highlighted
some of the issues working against the ability to pick
up a cancer diagnosis sooner. Barriers to early diagno-
sis in the UK include low public awareness of signs
and symptoms, practical difficulties with making
appointments and poor uptake of screening. Patients
might delay visiting their GP because of embarrass-
ment, attribution of symptoms to age or comorbidities
and not wanting to ‘bother the doctor’ or be a burden
to the NHS.27 The national series of ‘Be Clear on
Cancer’ campaigns is aiming to raise awareness of
cancer symptoms among the general public and
encourage early presentation to primary care.
Barriers to patients accessing care are lack of direct
access to diagnostic investigations for GPs, poor com-
munication between primary and secondary care ser-
vices, and pressure on GPs to avoid inappropriate
referral. The latest National Institute for Health and
Care Excellence (NICE) guidelines for symptomatic
referral have lowered the threshold to a positive pre-
dictive value of 3%28 to capture more patients and
cut time spent on testing, waiting for results and
reconsultation. However, rates of investigation in the
UK remain lower than in many other countries.29
Waiting times for colonoscopy in England have
increased because diagnostic capacity is so stretched.30
A new standard of 28 days from referral to diagnosis
and communication of results for 95% of patients has
been set for 2020. Thus, methods to improve diagno-
sis and exclusion must be considered now.
The Accelerate, Coordinate, Evaluate programme
(ACE) was introduced to improve and test new diag-
nostic pathways in the UK. Wave 1 supported uniform
implementation of best practice, which, in some areas,
has reduced endoscopy waiting times by at least
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10 days so far. Wave 2 will involve piloting new diag-
nostic pathways for patients with non-specific but con-
cerning symptoms through multidisciplinary diagnostic
clinics. ACE has also encouraged thinking on issues
such as the potential for expert diagnosticians (for
example gastroenterologists or specialised GPs) and
clearer guidelines on when referrals are inappropriate;
GPs see many patients with non-specific gastrointestinal
symptoms, making those at risk of cancer hard to
identify.
THE VIEW FROM PRIMARY CARE
Earlier access to definitive tests
Dr Terry Bowley, Macmillan GP advisor, opened the
discussion on the interface between primary and sec-
ondary care.
Despite an 18% increase in the NHS budget since
2005/2006, funding for GP care has dropped by 8%
in real terms. This drop has had an impact on the size
of the workforce, which is delaying access to health-
care professionals, with obvious implications for early
diagnosis.
A GP might see eight or nine new cases of cancer
per year and 30–40 patients (based on an average list
size of 2000 patients per GP) living with cancer or the
consequences of treatment at any given time. While
GPs see relatively few new cancer diagnoses per year,
they see a huge number of patients where malignancy
is a possibility. GPs, therefore, prefer to refer patients
via the 2-week wait pathway to rule out cancer rather
than wait for red-flag symptoms to develop. Patients
with vague symptoms, however, might need to be
reviewed several times by the GP before referral,31 32
and waiting times for investigations, such as ultrason-
ography, can cause further delay. NICE guidance from
2015 has been based on positive predictive values.
Reference values are available for many common
cancers and their presenting symptoms. Macmillan, in
collaboration with BMJ Informatica, has devised a
support tool that is easily incorporated into general
practice software and which is aimed at helping GPs
in clinical decision-making and referring patients with
suspected cancer.33 The tool has a symptom checker
that enables GPs to calculate percentage risk values
for specific cancers. It is also a ‘prompt’ functionality
that picks up symptoms coded by GPs in previous
consultations and highlights when patients are at
increased risk of certain cancers. These prompts are
especially helpful if patients do not always see the same
GP. Assessment of the use of this tool showed that it
changed decision-making in 50% of cases and that 20%
of referrals would not have been made if the tool had
not been used.33 Performance in relation to outcomes,
such as early diagnosis, is being assessed in ACE.
Living with cancer
In her presentation, Professor Jane Maher, Macmillan
Cancer Support, noted that improving outcomes in
cancer is not just about early diagnosis, but must also
take into account people living with cancer. There are
200 different cancers that can roughly be separated
into three broad categories: good outcomes (the
largest category, with life expectancy of at least
10 years), intermediate outcomes (life expectancy 1–
5 years) and poor outcomes (life expectancy up to 2
years).34 Patients in the intermediate group are gener-
ally the least visible but often undergo many lines of
cancer treatments.35
Better quality of life in the good group and survival
in the poor group are needed to improve cancer out-
comes. Costs are highest in survivors who live longest
after cancer treatment is completed and accumulate
after cancer treatment has ended (figure 2).36 They
might also be compounded by coexisting disorders,
such as hypertension, obesity, mental health issues and
chronic heart and kidney disease. Currently, 2.5 million
people in the UK are living with cancer, which is
400 000 more than in 2010, and the number is increas-
ing by around 3% per year.37 Although an extremely
positive step, more and older people are living with
consequences of cancer and treatment for longer and,
therefore, are not necessarily living well.38 39
The Independent Cancer Taskforce40 has published
recommendations to improve cancer outcomes,
including reducing and managing the long-term con-
sequences of treatment. Cancer can be separated into
three main categories: rare and complex (several
hundred patients requiring highly specialist care),
intermediate (tens of thousands of people who need
proactive care) and common (hundreds of thousands
of people with a broad range of risks and require-
ments). Guidelines are available from Macmillan for
GPs on the management of treatment consequences,
including when to refer and where to find educational
resources for patients. The Royal College of General
Practitioners has implemented a 1-year project that
aims to raise awareness and assess outcomes for conse-
quences of treatment. It will use surveys of GPs’
awareness of consequences of treatment to create a
GP ‘toolkit’ for identification and management of
patients at risk.
THE VIEW FROM SECONDARY CARE
Endoscopy in gastrointestinal cancer
Dr Andrew Veitch, New Cross Hospital, Wolverhampton,
and immediate past vice president (endoscopy) of the
British Society of Gastroenterology, noted that endos-
copy is integral to the diagnosis, prevention and treat-
ment of gastrointestinal cancers, especially upper
gastrointestinal cancers. To improve outcomes, the
time to diagnosis needs to be shortened and the detec-
tion rate for early neoplasia increased.
The incidence and mortality for oesophageal cancer
in the UK are the highest in Europe and are increas-
ing, although for stomach cancer they are reducing.41
The average rate for missed upper gastrointestinal
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cancers within 3 years of gastroscopy worldwide is
roughly 8% (range 2–40%). Many of these cancers may
have been treatable endoscopically if detected earlier.
Various standards have been developed for upper
gastrointestinal endoscopy, but these focus mainly on
mechanistic and safety factors. For example, of 22 key
performance indicators in the American Society for
Gastrointestinal Endoscopy quality standards,42 only
two relate to mucosal visualisation. In the UK, diag-
nostic gastroscopy is allocated 20 min, but the proced-
ure takes <5 min. Other positive changes to improve
detection that could also be made through training are
dedicated surveillance lists, sedation of patients, clean-
ing of the gastrointestinal tract (a common practice in
the caecum/rectum for colonoscopy) with mucolytics
or washing and photo-documentation to reveal and
record subtle lesions.
Another priority for gastrointestinal cancers is to
improve the evidence base. Important research direc-
tions include confirmation of whether the incidence
of early gastric neoplasms in Western populations is
sufficient to warrant a change of practice and whether
early endoscopic intervention in high-grade dysplasia
or intra-mucosal carcinoma will influence the natural
history of the disease.
Endoscopy capacity
Hilary Brown and Steve Wyatt presented data from
their study undertaken at the University of
Birmingham to assess endoscopy capacity across
England and which was commissioned by Cancer
Research UK.43 Surveys and interviews identified
several key workforce issues, including staff recruit-
ment (of all staff groups, but particularly nurses) and
retention, which were exacerbated by staff shortages,
and the training of inexperienced staff to take on
scoping work. Units were finding it challenging to con-
tinue to improve efficiency, although at the time of the
study the Productive Endoscopy Toolkit had only just
been introduced. Several factors, including public cam-
paigns to raise awareness of symptom, were increasing
demand and thereby the pressure on units, which in
some instances was adversely affecting surveillance
cases and non-urgent assessments. New technology
and tests, such as CT colonography, have increased the
complexity of procedures and, hence, time pressures.
Nevertheless, some units were making improvements
in productivity by paying closer attention to the teams
and having well-trained administration staff.
Modelling of the potential effects of changes in
gastrointestinal endoscopy activity estimated that
demand would reach 2.4 million endoscopies in
2019/2020, an increase of roughly 44% (6.5% per
year). Around a quarter of growth was estimated to be
driven by demography and population health status
factors and the remainder was driven by NHS factors
and new technology. The biggest single contributor
was the roll-out of the BCSP (figure 3). Use of
Figure 2 Costs of cancer survival.36
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endoscopy and flexible sigmoidoscopy was predicted
roughly to double, and identification of cancer through
symptoms and screening to increase substantially.
Reductions in non-attendance by patients offer only a
limited opportunity to free up endoscopy capacity.
Investment in the workforce through careful job
planning and training was recommended to address
the projected increase in demand. Joint Advisory
Group (JAG) accreditation and use of the Productive
Endoscopy Toolkit were encouraged to further
improve efficiency, as were engagement with commis-
sioners and increased collaboration between primary
and secondary care. Finally, better reporting for non-
screening and screening activities could improve stra-
tegic planning.
Since the study, the government has introduced a
training scheme for 200 further non-medical endosco-
pists in England and pledged up to £300 million more
investment in diagnostics per year by 2020. The
system, however, is likely to remain under pressure,
and in a time of austerity, the interplay between differ-
ent initiatives and interventions, such as the full
roll-out of the bowel scope screening programme and
the introduction of FIT, must be considered in terms
of maximising impact and value for money.
OESOPHAGEAL CANCER
Professor Rebecca Fitzgerald, University of Cambridge,
discussed early detection of oesophageal cancer. In
Western countries, the incidence of oesophageal adeno-
carcinoma has been increasing. Outlook is poor, with
overall 5-year survival of 13%, but can be improved
with early diagnosis by up to 80–90% in patients with
high-grade dysplasia or stage T1a disease at presenta-
tion and 60% for stage T1b submucosal disease.
Unfortunately, around 70% of patients present with
stage 3 disease or worse. Barrett’s oesophagus is a pre-
cancerous stage at which it might be useful to act to
detect or prevent possible cancer. Although most
people who progress to Barrett’s oesophagus do not
develop cancer, 0.3% per year do. Ablation therapy
can be preventive.44 45
The NICE guideline for Barrett’s oesophagus
recommends against offering endoscopy routinely for
diagnosis, but suggest considering it for patients with
gastro-oesophageal reflux disease, after discussion
about risk factors and preferences.46 The previous age
limit for referral has been removed in recognition of
patients age 35–44 years being more likely than older
patients to present as emergency cases.47
Endoscopic assessment of all patients with reflux
is not feasible and, therefore, prioritisation is essen-
tial. In the USA, around 10 000 people per year
have Barrett’s oesophagus, of whom only about 7%
develop oesophageal adenocarcinoma. Among 30
million individuals who have reflux disease, 90% do
not undergo endoscopy yet account for around 52%
of people who develop oesophageal adenocarcin-
oma and, therefore, this could be a pool worth
investigating (figure 4).48 Patients with reflux or
dyspepsia could be identified and investigated.
However, owing to the high number of investiga-
tions that would be required, an alternative to
endoscopy would be helpful.
Cytosponge is one such alternative. This device is
swallowed in a capsule that dissolves in 5 min, after
Figure 3 Modelled changes in gastrointestinal endoscopy activity 2013/2014 to 2019/2020.43 2WW, 2-week wait; BCSP, Bowel
Cancer Screening Programme; FIT, faecal immunochemical test; FOBT, faecal occult blood test; NICE, National Institute for Health and
Care Excellence.
Forgacs I, et al. Frontline Gastroenterology 2018;9:49–61. doi:10.1136/flgastro-2016-10071354
Education
group.bmj.com on February 28, 2018 - Published by http://fg.bmj.com/Downloaded from 
which the sponge is pulled out through the mouth by
the attached string. It collects cell samples from the
length of the oesophagus that can be assayed for
disease biomarkers.21 44 49 Sensitivity for Barrett’s
oesophagus is 73–90% and improves with increasing
length of Barrett’s segments.50 51 Furthermore, costs
are lower than those for endoscopy plus endotherapy
in early cancers.52 For low-risk patients, testing with
Cytosponge every 3 years would be appropriate, with
endoscopy referral if dysplasia develops.53 Gene
mutations, such as in TP53, which are associated with
high-grade dysplasia Barrett’s oesophagus, might help
to stratify patients further and prompt immediate
endoscopy.54–56
PANCREATIC CANCER
Professor Stephen Pereira of University College
London introduced his presentation by saying that
“pancreatic cancer is in such a bad state that things
can only get better”. There have been no improve-
ments in survival in the past 20–30 years. More than
half of patients are seen as emergencies, and 5-year
survival is only around 4%,57 yet pancreatic cancer is
allocated only 1% of cancer research funding.
The UK government has highlighted the need for
screening, access to care, earlier diagnosis and
improved patient experience for people with pancre-
atic cancer. Small T2 lesions are associated with much
better survival than tumours >3 cm. Importantly,
there are windows of opportunity for diagnosis and
detection of at-risk patients before symptoms develop.
In an at-risk cohort, 91% of patients had relevant
symptoms in the 2 years before diagnosis, such as
abdominal pain, indigestion, change in bowel habits,
back pain and nausea, but saw GPs a median of three
times (range 0–22) before referral.58 However, indi-
vidual symptoms are often vague, although they
increase in frequency strikingly in the year before
diagnosis (figure 5) and the visits tended to be
clustered in that period. Creating an algorithm to
combine and score specific alarm symptoms would be
helpful.
To encourage early diagnosis, one programme is the
Early Diagnosis of Abdominal Symptoms project,
which uses cross-sectional information to calculate
risk in multidisciplinary diagnostic centres to which
GPs have direct access. There are four pilot pathways
to referral: painless jaundice, >3 kg weight loss, non-
specific abdominal pain and two visits to accident and
emergency or the GP with severe unexplained abdom-
inal pain. Several centres in the UK offer screening of
people with family history of pancreatic cancer with
or without relevant gene mutations. Opportunistic
identification of cystic lesions in the pancreas should
prompt further investigation. Patients with serous or
mucinous or indeterminate cysts might require inter-
vention or ongoing surveillance.
Several imaging modalities, such as CT MRI, en-
doscopy, ultrasonography and endoscopic retrograde
Figure 4 Identifying possible populations at risk of oesophageal cancer.48 GERD, gastroesophageal reflux disease.
Figure 5 Incidence and timing of common symptoms in
pancreatic cancer before diagnosis.58
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cholangiopancreatography sampling, are emerging as
diagnostic approaches for pancreatic cancer. Good
progress in biomarker discovery has been made in the
past 24 months. Use of 200 000 serum samples gath-
ered for the United Kingdom Collaborative Trial of
Ovarian Cancer Screening as a resource has enabled
proteomics analysis. In the pre-diagnosis setting,
CA19-9 and CA125 have shown good performance as
pre-clinical biomarkers at least 1 year before diagno-
sis,59 and further studies are underway. Various pro-
teins in urine, which can be collected non-invasively
and is simpler to analyse than blood, correlate
strongly with precursor lesions.60 Assessment of bio-
markers might, therefore, extend the window of
opportunity for diagnosis of pancreatic cancer by
years,61 although whether they would improve detec-
tion in at-risk groups needs to be assessed.
Endoscopy of the pancreas is difficult and carries
the risk of pancreatitis. Confocal laser endomicro-
scopy and real-time molecular imaging with fluores-
cing proteins offer potential new applications in
addition to non-invasive imaging.
“BE CLEAR ON CANCER” CAMPAIGN
Public Health England, the Department of Public
Health and the NHS are taking a collaborative
approach to improve awareness of cancer with the
“Be Clear on Cancer” campaign, which was discussed
by Mr William Allum of the Royal Marsden NHS
Foundation Trust. Launched in 2010/2011, the cam-
paign was developed to contribute to the govern-
ment’s commitment of saving 5000 additional lives
per year by 2014/2015.28 “Be Clear on Cancer” con-
tinues to be an integral part of work to improve early
diagnosis. The campaigns are targeted at people older
than 50 years and aim to raise awareness of symptoms
of various cancers, including upper gastrointestinal
cancer, and encourage people to see their GP without
delay.
To design campaigns, public understanding of the
relevance of symptoms to cancer was surveyed. For
upper gastrointestinal cancer, heartburn, dyspepsia
and dysphagia were selected as symptoms to promote.
Dysphagia needed clarification, but heartburn was
well understood. Seven local pilots were done first,
followed by regional and national campaigns.
Campaign activity included advertising in national
media (television, press and radio), digital adverts tar-
geted at people shopping for heartburn medication,
face-to-face events and a supporting programme of
public relations. Leaflets and posters were distributed
to GP surgeries and these advertisements also featured
on pharmacy bags.
Pharmacists repeatedly selling over-the-counter or
prescription preparations to an individual were
encouraged to mention the campaign. Several national
pharmacy chains also carried advertising to encourage
these people to see their GPs.
For the national campaign, a module on gastrointes-
tinal cancer on Doctors.net.uk was made available,
which had reasonable uptake. For the regional cam-
paign, the number of urgent GP referrals (2-week
wait) increased, as did the number of cancers diag-
nosed after these referrals in the target age group.62
Full analysis of the data from the national campaign is
pending and will include how endoscopy services
have been affected and other potential knock-on
effects.
GASTROINTESTINAL CANCER: DOING BETTER IN
AUSTERE TIMES
Referral
There is currently roughly a 10% survival deficit for
gastrointestinal cancer in the UK compared with
similar countries, began Michael Machesney from
Barts Health NHS Trust. Cancers with lower preva-
lence have their own clinical reference groups and
budgets, whereas common cancers have many clinical
commissioning groups (CCGs). The interface for GP
referral to secondary care needs to be developed.
Enabling GPs to commission services that would
produce good data and from groups that will make
those data available for interpretation would be
useful. Services should also address variation, develop
strategies for early diagnosis and improve treatment
safety and follow-up. It is hoped that the shift to early
diagnosis will also improve the safety of treatment.
Patients with CRC are mainly referred through GPs,
but around a quarter still initially present as emer-
gency cases.63 The speed of GP referral can vary sub-
stantially64 and the cycle of tests and reassessment can
be costly and time-consuming. Direct access to ser-
vices on the request of GPs or after triage of patients
by the hospital could send the most urgent cases
straight to testing. Finally, the recurring limitations on
endoscopy capacity must be resolved.
Screening uptake can be improved if patients are
contacted directly.65 GPs are frequently unaware of
whether their patients have participated in screening.
In some cases, GPs receive formal notification, but in
others non-participation might be marked merely by a
non-flagged read code. The BCSP does not include
people aged 50–54 years, despite good preventive
value with bowel endoscopy in these patients.
Including younger age groups in screening pro-
grammes might be a cost-effective way to increase
detection in low-resource regions.
Commissioning
Dr Michael Glynn, National Clinical Director for GI
and Liver Services, NHS England, discussed commis-
sioning in austere times and emphasised that commis-
sioning for value is particularly important and needs
to be information based. The national data released
by Public Health England show that diagnosis of stage
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1 and 2 CRC varies by around 40–50% across
CCGs.66
Rather than trying to explain away these variations,
they should be seen as opportunities to do better. The
Right Care Approach (http://www.rightcare.nhs.uk)
has been set up to maximise value at the individual
and population levels. CCGs are invited to use The
NHS Atlas of Variation in Healthcare (figure 6)67 to
investigate differences, such as burden of disease and
treatment, and to address these in five key strands:
clinical leadership, indicative data, clinical engage-
ment, evidential data and effective process. For
example, if all providers in England were to match
the day-case surgery rates for cholecystectomy in the
upper quartile, the estimated annual saving could
release more than £64 million.
For CRC, several aspects would need to be
addressed, including local awareness (eg, GPs introdu-
cing campaigns), primary care systems (eg, flagging
symptoms of concern to patients and making refer-
rals), commissioning of services and implementing
appropriate service models. Careful attention is
needed to ensure adequate provision of pathology ser-
vices. These services also need to be improved, but
have not traditionally been at the forefront of CCG
attention, and even seem to have fallen off the CCG
radar. Changes leading to early diagnosis should in
turn produce substantial savings through less treat-
ment of stage 3 and 4 disease, as well as saving lives.
Research in primary care
Professor Roger Jones, King’s College London, and
Editor, British Journal of General Practice, began his
presentation by stating that cancer has become a head-
line problem in general practice. To augment the
changes that are required, general practices and GPs
must drive towards definitive diagnosis earlier. How
patients respond to information, campaigns and symp-
toms needs to be more clearly understood, and GPs
need to be better engaged. The propensity of GPs to
explore and act on groups of symptoms varies sub-
stantially, which might also need to be addressed.
The training of GPs over the past 20 years has often
emphasised a watch and wait approach to diagnosis,
Figure 6 Percentage of new cancers that were diagnosed at stage 1 or stage 2 by clinical commissioning groups (CCGs), 2013.67
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but must now move towards making more timely and
accurate diagnoses. Thresholds for investigation also
need to be lowered to improve access to care for
patients. Computer-assisted tools to help with assess-
ment of symptoms are very useful, but many include
mainly late-stage symptoms (eg, weight loss), which
will not improve early diagnosis. Safety-net systems
(eg, proactive follow-up) need to be put in place. For
the many cancers with ‘whispering’ symptoms, contin-
ued assessment and possible retesting if results do not
indicate cancer will be important.
Overall, however, the key to earlier diagnosis will
be collaborative research between primary and sec-
ondary care.
DISCUSSION
The audience was invited to raise questions and
discuss any of the issues raised throughout the confer-
ence. Here were present a selection of questions and
answers provided by the speakers and other audience
members.
▸ The JAG data website says that 93% of key trusts are
participating in the JAG standards accreditation pro-
gramme and that 66% are currently accredited. As
timing targets are part of this scheme, why are they not
being met? One centre lost accreditation because of this
issue, and it could lead to a domino effect.
– Good progress has been achieved, but all the quick
wins have been used up and now services are experi-
encing diminishing returns from changes. The biggest
challenge is still the workforce gap (including gastro-
enterologists), with 30% of roles unfilled. All units
need to improve effectiveness of staff.
▸ The workforce is grappling with the logistics of early
diagnosis. In the meantime, many patients, including a
lot without cancer, remain in the system. Is the system
becoming anti-patient?
– Public expectation has been set up for early diagnosis,
but this increases a risk of damage to patients who
do not have cancer, which needs to be limited.
Multidisciplinary approaches might serve these patients
better. For example, in Denmark, the health service
does not just rule out cancer, it also asks what else
might be wrong with those patients.
– Targets can lead to patients being ‘bounced’ between
primary and secondary care. The multidisciplinary
approach in ACE might improve this effect.
– Data are crucial. Many are available for people with
cancer but few for the people who are referred and
do not have cancer, and better tracking of these
patients is needed.
▸ 25% of referred patients are older than 80 years, but
they are not being caught by screening. Even the
BCSP has not increased screening uptake to more
than 60%.
– The ambition for 2020 is 75% screening uptake.
Macmillan are working with GPs to try to improve
the role they can play in raising awareness of
screening. An ambition is to have a Macmillan GP in
all CCGs.
– Data are being gathered by Macmillan on the fitness
of older people to withstand various procedures.
– In terms of changing from gFOBT to FIT, now could
be a good time. Also, starting screening from younger
ages could mean that it becomes the norm and is
accepted sooner. The introduction of FIT is expected
to increase uptake by around 10%. Direct contact
with patients is effective, and the UK has better
uptake than in countries that do not employ direct
contact, but having GPs endorse (but not asking them
to carry out) testing would probably improve uptake
further. Roll-out of new methods must not impinge
on the public making informed choices, including
refusal. Targeted approaches might also help. For
example, the gFOBT test was found to be unpopular
among the Asian community in Leicester because
Muhammad is a common name, but as it is also the
Islamic prophet’s name, writing it on a card next to
faeces is particularly distasteful.
▸ The Danish health system differs from those in other
Nordic countries and is more similar to the UK primary
care system. Therefore, are GPs the problem?
– Problems with late diagnosis are not all the fault of
GPs, but anything that can help GPs refer these
people should be approved. Survival in Denmark
seems to have improved more quickly than in the
other Nordic countries because of changes in referral
patterns, which are now being copied.
▸ How can interaction between primary and secondary
care be improved (eg, by access to more information,
etc)?
– Direct access to all investigations might not be possible
depending on the setup.
– General practice is on its knees, but by the time it gets
off its knees things will be very different (eg, technol-
ogy and methods of communication). Perhaps it
should be left alone to recover and adapt by itself.
– Electronic communication has helped the system
enormously.
▸ If GPs see so few patients with cancer per year, how easy
will it be to educate them and other primary care staff to
improve detection?
– Improved relationships between healthcare providers
and knowledge of practitioners at all levels can make a
difference.
– Telephone triage by nurses who can do colonoscopy
can help to ensure that patients are suitable for the
procedure before referral and that the preparation
requirements are met.
SUMMARY
Substantial steps are being made towards early diagno-
sis. A range of tools are available to help GPs appro-
priately categorise early symptoms during routine
consultations. Various promising new tests and devices
are being explored, especially for cancers that
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frequently present at late stages. The continuing
increase in demand on endoscopy services is a major
concern, not least because of the shortage of trained
practitioners and other healthcare staff. However,
screening and collaborative streamlining initiatives
might help to improve the relevance of referrals. The
question posed in the title of the conference was rhet-
orical, but a positive answer seems potentially achiev-
able, even in austere times, through facilitating uptake
of screening, working to develop the primary–second-
ary care interface, educating the public and by pro-
tecting funds for research.
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